News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
228,308 Results
Type
Article (7174)
Company Profile (16)
Press Release (221118)
Multimedia
Podcasts (3)
Webinars (1)
Section
Business (63142)
Career Advice (295)
Deals (14771)
Drug Delivery (28)
Drug Development (36801)
Employer Resources (24)
FDA (6415)
Job Trends (4909)
News (121836)
Policy (11632)
Tag
Academia (567)
Accelerated approval (2)
Adcomms (7)
Allergies (37)
Alliances (14778)
ALS (28)
Alzheimer's disease (602)
Antibody-drug conjugate (ADC) (42)
Approvals (6462)
Artificial intelligence (105)
Autoimmune disease (10)
Automation (3)
Bankruptcy (147)
Best Places to Work (4609)
BIOSECURE Act (2)
Biosimilars (21)
Biotechnology (18)
Bladder cancer (57)
Brain cancer (15)
Breast cancer (111)
Cancer (1185)
Cardiovascular disease (70)
Career advice (259)
Career pathing (4)
CAR-T (90)
Cell therapy (222)
Cervical cancer (12)
Clinical research (31239)
Collaboration (311)
Compensation (90)
Complete response letters (7)
COVID-19 (724)
CRISPR (19)
C-suite (78)
Cystic fibrosis (37)
Data (1346)
Denatured (1)
Depression (19)
Diabetes (112)
Diagnostics (2233)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (48)
Drug pricing (41)
Drug shortages (17)
Duchenne muscular dystrophy (40)
Earnings (33372)
Editorial (14)
Employer branding (1)
Employer resources (19)
Events (31128)
Executive appointments (252)
FDA (7099)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (270)
Gene editing (48)
Generative AI (10)
Gene therapy (135)
GLP-1 (185)
Government (1254)
Grass and pollen (2)
Guidances (40)
Healthcare (6146)
Huntington's disease (5)
IgA nephropathy (16)
Immunology and inflammation (36)
Indications (17)
Infectious disease (786)
Inflammatory bowel disease (61)
Inflation Reduction Act (5)
Influenza (24)
Intellectual property (54)
Interviews (45)
IPO (8037)
IRA (17)
Job creations (571)
Job search strategy (221)
Kidney cancer (8)
Labor market (5)
Layoffs (40)
Leadership (4)
Legal (2100)
Liver cancer (41)
Lung cancer (166)
Lymphoma (85)
Machine learning (2)
Management (7)
Manufacturing (106)
MASH (38)
Medical device (4587)
Medtech (4588)
Mergers & acquisitions (7094)
Metabolic disorders (284)
Multiple sclerosis (41)
NASH (8)
Neurodegenerative disease (26)
Neuropsychiatric disorders (4)
Neuroscience (815)
NextGen: Class of 2025 (1500)
Non-profit (712)
Obesity (140)
Opinion (76)
Ovarian cancer (54)
Pain (38)
Pancreatic cancer (48)
Parkinson's disease (68)
Partnered (5)
Patents (138)
Patient recruitment (65)
Peanut (17)
People (14545)
Pharmaceutical (8)
Pharmacy benefit managers (6)
Phase I (9974)
Phase II (13744)
Phase III (10304)
Pipeline (756)
Policy (34)
Postmarket research (796)
Preclinical (3664)
Press Release (9)
Prostate cancer (53)
Psychedelics (11)
Radiopharmaceuticals (119)
Rare diseases (158)
Real estate (1004)
Recruiting (7)
Regulatory (9168)
Reports (13)
Research institute (510)
Resumes & cover letters (39)
Rett syndrome (4)
RNA editing (2)
RSV (16)
Schizophrenia (28)
Series A (44)
Series B (31)
Service/supplier (2)
Sickle cell disease (23)
Special edition (2)
Spinal muscular atrophy (31)
Sponsored (14)
Startups (677)
Stomach cancer (5)
Supply chain (26)
Tariffs (3)
The Weekly (1)
Vaccines (170)
Venture capitalists (5)
Weight loss (77)
Women's health (6)
Worklife (4)
Date
Today (85)
Last 7 days (413)
Last 30 days (1201)
Last 365 days (15826)
2025 (4975)
2024 (16932)
2023 (19102)
2022 (22239)
2021 (23635)
2020 (21800)
2019 (14449)
2018 (10636)
2017 (11459)
2016 (9542)
2015 (11736)
2014 (8102)
2013 (5877)
2012 (6040)
2011 (6749)
2010 (6216)
Location
Africa (176)
Alabama (16)
Alaska (2)
Arizona (55)
Arkansas (3)
Asia (17573)
Australia (4853)
California (2937)
Canada (1138)
China (247)
Colorado (123)
Connecticut (166)
Delaware (61)
Europe (28050)
Florida (435)
Georgia (69)
Idaho (6)
Illinois (214)
India (20)
Indiana (123)
Japan (93)
Kansas (14)
Kentucky (5)
Louisiana (5)
Maine (36)
Maryland (357)
Massachusetts (2094)
Michigan (51)
Minnesota (105)
Missouri (36)
Montana (11)
Nebraska (8)
Nevada (41)
New Hampshire (36)
New Jersey (1014)
New Mexico (3)
New York (935)
North Carolina (396)
North Dakota (2)
Northern California (1295)
Ohio (64)
Oklahoma (1)
Oregon (7)
Pennsylvania (689)
Puerto Rico (7)
Rhode Island (8)
South America (302)
South Carolina (11)
Southern California (1129)
Tennessee (42)
Texas (444)
United States (10821)
Utah (68)
Virginia (78)
Washington D.C. (17)
Washington State (345)
West Virginia (2)
Wisconsin (12)
228,308 Results for "nodthera limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NodThera’s Oral NLRP3 Inhibitor NT-0796 Enhances and Sustains Weight Loss in Combination with GLP-1
April 30, 2025
·
5 min read
Drug Development
NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk
NodThera announces positive data from its Phase Ib/IIa cardiovascular risk study in inflamed obese subjects, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796, on inflammatory, cardiovascular and metabolic risk parameters.
June 12, 2024
·
4 min read
Business
NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer
NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, announces the appointment of Daniel Swisher as Chief Executive Officer, to strengthen the Company’s commercial capabilities, effective immediately.
May 28, 2024
·
5 min read
Drug Development
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
NodThera today announces positive data from its Phase Ib/IIa study in Parkinson’s disease patients, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796, on inflammatory and disease-specific biomarkers in the blood and cerebrospinal fluid (CSF).
March 7, 2024
·
5 min read
Press Releases
NodThera Named a ‘Fierce 15’ Company by Fierce Biotech
August 5, 2024
·
2 min read
Press Releases
NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer
August 1, 2024
·
4 min read
Parkinson’s disease
Breaking the Cycle of Inflammation in Parkinson’s Disease
Halia Therapeutics, NodThera and Gain Therapeutics target neuroinflammatory processes in hopes of modifying the course of Parkinson’s progression.
July 15, 2024
·
4 min read
·
Jill Drachenberg
Press Releases
Health Canada approves IMFINZI® (durvalumab) as the first and only immunotherapy regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC)
April 10, 2025
·
6 min read
Press Releases
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
April 14, 2025
·
5 min read
Press Releases
Dynavax Adopts Limited-Duration Stockholder Rights Plan
October 30, 2024
·
5 min read
1 of 22,831
Next
